Randomization and blinding are regarded as the most important tools to help reduce bias in clinical trial designs. Randomization is used to help guarantee that treatment arms differ systematically only by treatment assignment at baseline, and blinding is used to ensure that differences in endpoint evaluation and clinical decision-making during the trial arise only from the treatment received and not, for example, the expectation or desires of the people involved. However, given that there are times when it is not feasible or ethical to conduct fully blinded trials, we discuss what can be done to improve a trial, including conducting the trial as if it were a fully blinded trial and maintaining confidentiality of ongoing study results. In this article, we review how best to design, conduct, and analyze open-label trials to ensure the highest level of study integrity and the reliability of the study conclusions.
LangTAStroupDF. Who knew? The misleading specificity of “double-blind” and what to do about it. Trials2020; 21: 697.
2.
PenićABegićDBalajićK, et al. Definitions of blinding in randomized controlled trials of interventions published in high-impact anaesthesiology journals: a methodological study and survey of authors. BMJ Open2020; 10: e035168.
3.
DevereauxPJMannsBJGhaliWA, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA2001; 285: 2000–2003.
4.
MontoriVMBhandariMDevereauxPJ, et al. In the dark: the reporting of blinding status in randomized controlled trials. J Clin Epidemiol2002; 55: 787–790.
5.
SchulzKFGrimesDA. Blinding in randomised trials: hiding who got what. Lancet2002; 359(9307): 696–700.
6.
BeggCChoMEastwoodS. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996; 276(8): 637–639.
7.
MoherDSchulzKFAltmanDG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol2001; 1: 2.
8.
AltmanDGSchulzKFMoherD, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med2001; 134(8): 663–694.
MayGSDeMetsDLFriedmanLM, et al. The randomized clinical trial: bias in analysis. Circulation1981; 64(4): 669–673.
11.
HowardJPShun-ShinMJHartleyA, et al. Quantifying the 3 biases that lead to unintentional overestimation of the blood pressure–lowering effect of renal denervation. Circ Cardiovasc Qual Outcomes2016; 9(1): 14–22.
12.
MonaghanTFAgudeloCWRahmanSN, et al. Blinding in clinical trials: seeing the big picture. Medicina2021; 57: 647.
13.
SchulzKFGrimesDAAltmanDG, et al. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ1996; 312: 742–744.
McCambridgeJSorhaindoAQuirkA, et al. Patient preferences and performance bias in a weight loss trial with a usual care arm. Patient Educ Couns2014; 95(2): 243–247.
16.
JüniPAltmanDGEggerM. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ2001; 323(7303): 42–46.
17.
MartinGLTriouxTGaudryS, et al. Association between lack of blinding and mortality results in critical care randomized controlled trials: a meta-epidemiological study. Crit Care Med2021; 49(10): 1800–1811.
18.
Beyer-WestendorfJBüllerH. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?J Thromb Haemost2011; 9: 2153–2158.
EllenbergSSFlemingTRDeMetsDL. Data monitoring committees in clinical trials: a practical perspective. Chichester: John Wiley & Sons, 2002.
21.
FDA. Guidance for clinical trial sponsors: establishment and operation of clinical trial data monitoring committees, https://www.fda.gov/media/75398/download (2006, accessed 17 December 2023).
22.
FlemingTRSharplesKMcCallJ, et al. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials2008; 5: 157–167.
23.
KahanBCDoréCJMurphyMF, et al. Bias was reduced in an open-label trial through the removal of subjective elements from the outcome definition. J Clin Epidemiol2016; 77: 38–43.
24.
AmitOBushnellWDoddL, et al. Blinded independent central review of the progression-free survival endpoint. Oncologist2010; 15(5): 492–495.
25.
DoddELKornELFreidlinB, et al. Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?J Clin Oncol2008; 26(22): 3791–3796.
26.
StoneAGebskiVDavidsonR, et al. Exaggeration of PFS by blinded, independent, central review (BICR). Ann Oncol2019; 30(2): 332–338.
27.
KahanBCRehalSCroS. Blinded outcome assessment was infrequently used and poorly reported in open trials. PLoS ONE2015; 10(6): e0131926.
28.
KahanBCCroSDoréCJ, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials2014; 15: 456.
29.
LindeKWittCMStrengA, et al. The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain. Pain2007; 128(3): 264–271.
30.
McLeodCNormanRLittonE, et al. Choosing primary endpoints for clinical trials of health care interventions. Contemp Clin Trials Commun2019; 16: 100486.
31.
De GruttolaVGClaxPDeMetsDL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a national institutes of health workshop. Control Clin Trials2001; 22(5): 485–502.
32.
PowersJHPatrickDLWaltonMK, et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health2017; 20(1): 2–14.
33.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther2001; 69(3): 89–95.
34.
Del ReACMaiselNCBlodgettJC, et al. Intention-to-treat analyses and missing data approaches in pharmacotherapy trials for alcohol use disorders. BMJ Open2013; 3: e003464.
35.
HollisSCampbellF. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ1999; 319: 670–674.
36.
ICH E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials, https://www.fda.gov/media/148473/download (2021, accessed 17 December 2023).
37.
FreidlinBKornELHunsbergerS, et al. Proposal for the use of progression-free survival in unblinded randomized trials. J Clin Oncol2007; 25(15): 2122–2126.
38.
FDA. Guidance for industry: adaptive designs for clinical trials of drugs and biologics, https://www.fda.gov/media/78495/download (2019, accessed 17 December 2023).
